Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World November 12, 2002 Michael Goldman	A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?
Bio-IT World January 21, 2005	Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Bio-IT World December 10, 2002 Arielle Emmett	Locus Focus Cheminformatics company Locus Discovery is a technology darling and an entrepreneur's dream, but it faces a dilemma over how much of its proprietary drug discovery software and data to reveal.
Bio-IT World April 15, 2003 Malorye Branca	Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Chemistry World February 2011	Idle cures Taking a coffee break could help find cures for cancer or Aids. Katrina Megget looks at the future of research that harnesses the computing power of the World Community Grid
Industrial Physicist Jennifer Ouellette	Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems
HHMI Bulletin Aug 2010 Richard Saltus	Three-Dimensional Cell Cultures Thinking big but starting small, Sangeeta Bhatia is closing in on her ambitious goal: growing human livers in the lab from scratch.
Bio-IT World January 13, 2003 John Dodge	Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets.
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Bio-IT World February 10, 2003 Salvatore Salamone	Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering.
Bio-IT World July 11, 2002 Malorye Branca	Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed.
Wired August 2003 Jennifer Kahn	The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine.
Bio-IT World March 10, 2003 Mark D. Uehling	Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Bio-IT World July 15, 2003	Millennium's PARIS Illuminates Pathways To address high-throughput-data challenges, Millennium Pharmaceuticals built the PAthway Resource and Information System, or PARIS -- a unique platform for combining knowledge from heterogeneous data sources in the construction of a pathway knowledgebase.
Pharmaceutical Executive July 30, 2007	Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs.
Bio-IT World June 2006 Kevin Davies	The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine.
Bio-IT World September 11, 2003 Mark D. Uehling	Fishing Chips The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may threaten the early leads of Biacore and Ciphergen -- and work so well that drug companies won't want them.
Chemistry World	Fishing for Chemical Answers to Biological Questions James K. Chen talks about chemical biology, his love for the outdoors and fly fishing.
Bio-IT World December 15, 2003 Zachary Zimmerman	Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology.
BusinessWeek September 23, 2010 Rob Waters	Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Knowledge@Wharton	A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies...
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Chemistry World February 12, 2014 Manisha Lalloo	Synthetic strategy targets 'undruggable' small RNAs Chemists in the US have found a way to predict small molecules that can target short pieces of RNA involved in some diseases, such as cancer.
Pharmaceutical Executive October 1, 2012 Ben Comer	Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.
IEEE Spectrum March 2011 Lucks & Arkin	Synthetic Biology's Hunt for the Genetic Transistor How genetic circuits will unlock the true potential of bioengineering
Chemistry World July 6, 2012	Protein power Tom Muir, professor of chemistry and molecular biology, Princeton University, US, is an expert in protein engineering and its application to studying cellular signalling networks.
HHMI Bulletin May 2010 Robert Tjian	Biomolecular Crowdsourcing A generation of web-savvy entrepreneurs has found a relatively cheap and effective approach to solving complex problems and soliciting ideas: toss out a challenge into a vibrant digital community and watch what happens.
HHMI Bulletin Spring 2013 Nicole Kresge	A Structural Toolbox Natalie Strynadka wants to design a better antibiotic. Her strategy: learn about the molecules bacteria use to invade cells. Her tool: structural biology.
Bio-IT World November 2005 John Russell	Optimizing Optimata Optimata continues to fine tune it's use of mathematics to identify optimum therapy regimes for cancer.
Bio-IT World April 2007 Vicki Glaser	Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.
IEEE Spectrum August 2006 Schoenbach et al.	Zap Extreme voltage could be a surprisingly delicate tool in the fight against cancer. The list of effects that scientists have achieved using nanoseconds-long pulses is growing rapidly, though their actual use as a medical treatment is still years away.
The Motley Fool June 21, 2010 Erin Kutz	Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week.
Chemistry World July 21, 2011 Elinor Richards	Cell Control to Change Cell Function US scientists can now control the reactions occurring inside cells.
Bio-IT World October 10, 2003 Jeffrey Skolnick	Protein Structure Prediction in Drug Discovery Indications are that structure prediction can assist in the automated assignment of proteins to known pathways.
HHMI Bulletin Aug 2011 Cassandra Willyard	A Faster Knockout With a virus, a needle, and an ultrasound machine, researchers have drastically cut the time it takes to disable a gene in mice.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Bio-IT World November 14, 2003 Jeff Augen	Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative.
Bio-IT World June 12, 2002 Karen Hopkin	Computational Biologists Join the Fold CASP5 competitors compare the best algorithms for modeling the 3-D structure of proteins -- an exercise that could lead to new insights into the pathogenesis and treatment of disease.
Bio-IT World February 18, 2004	Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
Bio-IT World August 2005	Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects.
Chemistry World June 23, 2015 Derek Lowe	Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example.
Bio-IT World August 15, 2005 Robert M. Frederickson	What's 'Post' About Postgenomic? Bioinformatics tools can help organize and study genomic sequences that were discovered in the '90s. The tools help with tasks like analyzing gene expression, predicting protein structure and function, and establishing networks of interacting protein in cells.
Bio-IT World April 15, 2003 Robert M. Frederickson	Protein Chemistry Surfaces Protein chips seek to do for protein expression profiling what DNA chips did for RNA expression.